The FDA Just Spent a Full Day on Testosterone for Menopausal Women

On September 17, 2026, the FDA’s Office of Women’s Health and its Center for Drug Evaluation and Research convened a full-day public workshop at the agency’s White Oak campus devoted entirely to one question: what do we actually know about testosterone in menopausal women, and what do we still need to find out?

For a hormone that women produce in greater quantity than estrogen across most of their lives, that is a remarkably overdue conversation. And the agency did something unusual alongside it — it opened a public docket, FDA-2026-N-5479, and invited women to put their own experience on the federal record.

Key Takeaways

• The FDA held a hybrid public workshop on September 17, 2026, hosted by the Office of Women’s Health and CDER, to examine the evidence and the gaps around testosterone use in menopausal women.
• There is still no FDA-approved testosterone product for women in the United States, despite approved female-specific products in the UK, Australia, New Zealand, and South Africa.
• Prescribing has moved anyway. Truveta data reported by Reuters shows the rate of women receiving a testosterone prescription rose 146% between January 2023 and July 2026.
• The evidence is strong for one indication — postmenopausal hypoactive sexual desire disorder (HSDD) — and genuinely insufficient for mood, cognition, bone, and muscle.
• The largest meta-analysis to date pooled 36 randomized controlled trials and 8,480 women, and found clear sexual-function benefit with a reassuring short-term safety profile.
• The real gap is duration: high-quality safety data does not extend past about 24 months, so long-term cardiovascular and breast outcomes remain unestablished.
• Public comments are open on Regulations.gov under docket FDA-2026-N-5479 until 11:59 p.m. ET on October 19, 2026. You do not need credentials to comment.

What Actually Happened in the Room

The workshop ran 9:00 a.m. to 4:30 p.m. ET, in person and virtually, and it was structured as three sessions that map almost exactly onto the three things standing between women and an approved product.

Speakers included Margaret Wierman, MD of the University of Colorado; James Simon, MD of George Washington University; Rajita Patil, MD, who directs the UCLA Comprehensive Menopause Program; Pelin Batur, MD of Cleveland Clinic; and urologist and sexual medicine specialist Rachel Rubin, MD. A menopause hormone therapy patient was given her own slot on the agenda — a detail worth noticing, because the absence of patient-centered outcome data is part of what is holding this file up.

The Gap That Made This Meeting Necessary

Here is the situation in plain terms. Testosterone has been approved and marketed for men in the United States for decades, in patches, gels, injections, and pellets. For women, there is not one approved product. The UK, Australia, New Zealand, and South Africa have female-specific formulations. American women do not.

What has filled that vacuum is off-label prescribing — often compounded, frequently not covered by insurance, and sometimes dosed by clinicians working without a female-specific label to guide them.

That growth curve is the reason the FDA could no longer treat this as a niche file. Women are already using testosterone. The question is whether they do it with an approved product, a validated dose, and a label — or without.

What the Science Actually Supports

This is the part I want to be precise about, because it is where marketing and evidence most often part ways.

The definitive dataset is a 2019 systematic review and meta-analysis in The Lancet Diabetes & Endocrinology by Islam and colleagues at Monash University, which pooled 36 randomized controlled trials covering 8,480 women. In postmenopausal women, testosterone significantly improved satisfying sexual event frequency, desire, arousal, orgasm, pleasure, responsiveness, and self-image, and reduced sexual distress and sexual concerns. Acne and unwanted hair growth were more common than with placebo. No serious adverse events were recorded.

The same analysis is equally clear about what it did not find. There were no demonstrated effects on body composition, musculoskeletal outcomes, or cognition — though the authors flag that few women contributed data to those endpoints. Oral testosterone worsened the lipid profile; non-oral routes such as transdermal cream or patch did not, which is why the transdermal route is preferred.

That picture is reinforced by the Global Consensus Position Statement on the Use of Testosterone Therapy for Women, endorsed in 2019 by a dozen international bodies including the Endocrine Society, the International Menopause Society, and what is now The Menopause Society. Its conclusion: the only evidence-based indication is postmenopausal HSDD, diagnosed after a full biopsychosocial assessment. It found insufficient evidence for cognition, and no demonstrated effect on mood, general wellbeing, bone mineral density, lean body mass, or muscle strength.

Testosterone is not a general-purpose vitality drug for women. It is a hormone with one well-supported indication, several plausible-but-unproven ones, and a safety file that stops at two years.

Where the Real Gaps Are

The FDA framed this meeting around knowledge gaps, and four of them do most of the work.

1. We cannot measure it well at female concentrations

A woman’s circulating testosterone is roughly an order of magnitude lower than a man’s. Many routine immunoassays were validated for the male range and lose accuracy at the low end, which is exactly where women live. An entire workshop slot was devoted to this problem. If you cannot measure the analyte reliably, you cannot define a therapeutic range, set a label, or run a trial that regulators will trust.

2. There is no female-dose product to study

Without an approved female formulation, trials and clinical practice both improvise — fractions of a male product, or compounded preparations that the Global Consensus statement explicitly declined to recommend because of insufficient efficacy and safety data. That is a circular problem: no product means thin data, and thin data means no product.

3. The safety file stops at about two years

This is the single most important gap. Short-term data are reassuring. But physiologic-dose safety data do not extend beyond roughly 24 months, which means the long-term cardiovascular and breast cancer questions are not answered — they are unasked. Anyone telling you testosterone is definitively safe for women over decades is going beyond the evidence, and anyone telling you it is definitively dangerous is doing the same thing in the other direction.

4. We have not agreed on what to measure

The FDA dedicated a session to clinical outcome assessments — how to capture what actually matters to patients. If a woman reports that her energy, strength, or sense of herself improved, and the trial instrument only counts satisfying sexual events per month, the trial will not see it. Building better outcome measures is unglamorous regulatory work, and it may be the thing that unlocks the rest.

What Needs to Happen Next

• A female-specific, physiologic-dose product. Other countries have one. An approved product brings a label, a defined dose, pharmacy consistency, and insurance pathways — and it ends the improvisation.
• Assay standardization. Reliable measurement at female concentrations, most likely through liquid chromatography–mass spectrometry rather than legacy immunoassays.
• Long-duration safety trials. Powered and followed long enough to speak to cardiovascular and breast outcomes, not just 12- to 24-week endpoints.
• Validated outcome measures beyond the bedroom. If energy, strength, and cognition are going to be studied honestly, the instruments have to be built and validated first.
• Trials in the women actually being treated. Much of the existing musculoskeletal data comes from small groups of women who were all on concurrent estrogen. That is not the whole population now taking testosterone.

How to Put Your Experience on the Record

The docket is the part most people will miss, and it is the part any woman reading this can act on. The FDA opened docket FDA-2026-N-5479 on Regulations.gov for broad public comment on the risks and benefits of testosterone use in menopausal women. It closes at 11:59 p.m. ET on October 19, 2026.

You do not need to be a clinician, and you do not need citations. The agency is asking for lived experience — which is precisely the data gap. If you choose to comment, the most useful submissions tend to describe your symptoms before treatment, what preparation and route you used, how long it took to notice a change, what actually improved, and any side effects you experienced. Comments may be submitted anonymously.

What This Means If You Are Considering Testosterone in Austin

Nothing about this meeting changes what is legal or available tomorrow. Off-label prescribing remains legal and remains common. What the meeting does is sharpen the standard a reasonable clinic should hold itself to while the science catches up.

At Victory Rejuvenate, that means a few specific commitments in how we approach testosterone as part of hormone therapy for women:

• We name the indication honestly. Low sexual desire causing distress after menopause is the evidence-based use. If your goal is energy, strength, or cognition, we will tell you the evidence there is not established, and we will not pretend otherwise to make a sale.
• We dose to the physiologic female range. Not the male range, not supraphysiologic. The consensus guidance is explicit that levels should not exceed those seen in healthy young women.
• We measure and re-measure. A baseline level before treatment, a re-check a few weeks in, and ongoing monitoring — along with the broader lab panel that puts a single hormone in context.
• We set a stopping rule. If there is no meaningful benefit within about six months, continuing is not a neutral decision. We change the plan.
• We treat testosterone as one input, not the answer. For most women in perimenopause and menopause, estradiol, progesterone, thyroid, sleep, and metabolic health do more of the work. Testosterone is a tool in that system, not a substitute for it.

The most encouraging thing about September 17 is not that the FDA reached a conclusion — it did not, and was never going to in one day. It is that the question is finally on the agency’s formal agenda, with a docket attached and an industry, research, and patient audience in the room. That is how a therapy moves from improvised to approved.

Frequently Asked Questions

Did the FDA approve testosterone for women?

No. The September 17, 2026 event was a public workshop to examine evidence and knowledge gaps, not an approval decision or an advisory committee vote. There is still no FDA-approved testosterone product for women in the United States. The workshop is intended to inform future research and potential drug development.

Is testosterone therapy for women legal right now?

Yes. Prescribing an approved drug off-label is legal and common in American medicine, and testosterone is prescribed to women this way today. What is missing is a product approved and labeled specifically for women, which is why dosing, formulation, and monitoring depend heavily on the clinician you choose.

What is testosterone actually proven to do for menopausal women?

The strongest evidence, from 36 randomized trials covering 8,480 women, supports improvement in sexual desire, arousal, orgasm, pleasure, and self-image, and a reduction in sexual distress, in postmenopausal women with hypoactive sexual desire disorder. Evidence for mood, cognition, bone density, and muscle strength is currently insufficient.

Is it safe?

Short-term data are reassuring: no serious adverse events were recorded in the pooled trials, and non-oral routes did not worsen lipids. The honest limitation is duration. Physiologic-dose safety data do not extend much beyond 24 months, so long-term cardiovascular and breast cancer risks are not established. Known side effects include acne and unwanted hair growth, and excessive dosing can cause voice deepening that may not fully reverse.

How do I submit a comment to the FDA?

Go to Regulations.gov and search for docket number FDA-2026-N-5479. Comments are open until 11:59 p.m. ET on October 19, 2026. No credentials are required, and you may submit anonymously.

Should I stop or start testosterone because of this meeting?

Neither, on the basis of a meeting alone. If you are currently on testosterone, this is a good moment to review your dose, your levels, and whether you are actually getting the benefit you started for. If you are considering it, ask the clinic which indication they are treating and what evidence supports it.

This article is educational and does not constitute medical advice. Testosterone is not FDA-approved for use in women in the United States; any use in women is off-label. Candidacy, dosing, and monitoring are determined individually at consultation, and individual results vary.